|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Medical management of gastric cancer:A 2014 update显示文摘Gastric cancer represents a serious health problem on a global scale. It is the second leading cause of cancer-related death worldwide. Novel therapeutic targets are desperately needed because the meager improvement in the cure rate of about 10% realized by adjunctive treatments to surgery is unacceptable as > 50% patients with localized gastric cancer succumb to their disease. Either postoperative chemoradiotherapy(United States),pre-and post-operative chemotherapy(Europe),and adjuvant chemotherapy after a D2 resection(Asia) can all be regarded as standards of care in the localized gastric cancer management. In metastatic disease the addition of trastuzumab to chemotherapy is standard of care in Her2 positive disease. In the HER2 negative population,the treatments remain limited.In the first line setting,the standard of care is a combination of fluoropyrimidine and platinum containing chemotherapy,with or without epirubicin or docetaxel.The results of targeted therapy trials have by and large been disappointing,but none of these trials looked at an appropriately enriched population.Finally there is a meager overall survival benefit in treating patients with metastatic disease in the second line setting,with either irinotecan,docetaxel or ramucirumab however none of these drugs have been compared head to head in a well-powered randomized controlled trial. | Elena Elimova Hironori Shiozaki Roopma Wadhwa Kazuki Sudo Qiongrong Chen Jeannelyn S Estrella Mariela A Blum Brian Badgwell Prajnan Das Shumei Song Jaffer A Ajani | 2014 | World Journal of Gastroenterology2014，20，38： | 10 |
| 2 | Evolution of gastric surgery techniques and outcomes显示文摘Surgical management of gastric cancer improves survival.However,for some time,surgeons have had diverse opinions about the extent of gastrectomy.Researchers have conducted many clinical studies,making slow but steady progress in determining the optimal surgical approach.The extent of lymph node dissection has been one of the major issues in surgery for gastric cancer.Many trials demonstrated that D2 dissection resulted in greater morbidity and mortality than D1 dissection.However,long-term outcomes demonstrated that D2 dissection resulted in longer survival than D1 dissection.In 2004,the Japan Clinical Oncology Group reported a pivotal trial which was performed to determine whether para-aortic lymph node dissection combined with D2 dissection was superior to D2 dissection alone and found no benefit of the additional surgery.Gastrectomy with pancreatectomy,splenectomy,and bursectomy was initially recommended as part of the D2 dissection.Now,pancreas-preserving total gastrectomy with D2 dissection is standard,and ongoing trials are addressing the role of splenectomy.Furthermore,the feasibility and safety of laparoscopic gastrectomy are well established.Survival and quality of life are increasingly recognized as the most important endpoints.In this review,we present perspectives on surgical techniques and important trials of these techniques in gastric cancer patients. | Hironori Shiozaki Yusuke Shimodaira Elena Elimova Roopma Wadhwa Kazuki Sudo Kazuto Harada Jeannelyn S.Estrella Prajnan Das Brian Badgwell Jaffer A.Ajani | 2016 | Chinese Journal of Cancer2016，35，8： | 9 |
| 3 | Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus显示文摘 | Richard G. Moore Amy K. Brown M. Craig Miller Donna Badgwell Zhen Lu W. Jeffrey Allard C.O. Granai Robert C. Bast Karen Lu | 2008 | Gynecologic Oncology2008，，2： | 3 |
| 4 | A survey of industrial model predictive control technology显示文摘 | S.Joe Qin Thomas A. Badgwell | 2002 | Control Engineering Practice2002，，7： | 2 |
| 5 | A survey of industrial model predictive control technology显示文摘 | Qin s J Badgwell T A | 2003 | Control Engineering Practice2003，11，7： | 1 |
| 6 | A survey of industrial model predictive control technology显示文摘 | Qin S J Badgwell T A | | 0，，07： | 1 |
| 7 | A survey of industrial model predictive control technology 显示文摘 | QIN S J BADGWELL T A | 2003 | Control Engineering Practice2003，11，7： | 1 |
| 8 | A survey of industrial model predic- tive control technology 显示文摘 | Qin S J Badgwell T A | 2003 | Control Engineering Practice2003，11，7： | 1 |
| 9 | Volume-controlled ventilation is made possible in infants by using compliant breathing circuits with large compression volume显示文摘 | Badgwell M Swan J Foster AC | 1996 | Anesth Analg1996，82，4： | 1 |
| 10 | New tumor markers: CA125 and beyond 显示文摘 | Bast RJ Badgwell D Lu Z | 2005 | Int J Gynecol Cancer2005，15，3： | 1 |
| 11 | A Survey of Industrial Model Predictive Control Technology显示文摘 | QIN S J BADGWELL T A | 2003 | Control Engineering Practice2003，11，： | 1 |
| 12 | Proteomic biomarkers apolipoprotein A1,truncated transthyretin and connective tissue activating protein Ⅲ enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer显示文摘 | Clarke CH Yip C Badgwell D | | 0，，： | 1 |
| 13 | Management of bevacizumab- associated bowel perforation : a case series and review of the literature 显示文摘 | Badgwell BD Camp ER Feig B | 2008 | Ann Oncol2008，19，3： | 1 |
| 14 | New tumor markers : CA125 and beyond显示文摘 | Bast RC Jr Badgwell D Lu Z | 2005 | Int J Gynecol Cancer2005，15，3： | 1 |
| 15 | New tumor markers: CA125 and beyond显示文摘 | Bast RC Jr Badgwell D Lu Z | 2005 | Int J Gynecol Cancer2005，15，3： | 1 |
| 16 | A survey of industrial model predictive control technology 显示文摘 | QIN S J BADGWELL A | 2003 | Control Engineering Practice2003，7，11： | 1 |
| 17 | Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus显示文摘 | Richard G. Moore Amy K. Brown M. Craig Miller Donna Badgwell Zhen Lu W. Jeffrey Allard C.O. Granai Robert C. Bast Karen Lu | 2008 | Gynecologic Oncology2008，，2： | 1 |
| 18 | A survey of industrial model predictive Control technology 显示文摘 | QIN S J BADGWELL T A | 2003 | Control engineering practice2003，11，7： | 1 |
| 19 | Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary HCG free beta subunit and hCG beta core fragment 显示文摘 | Badgwell D Lu Z Cole L | 2007 | Gynecology2007，106，3： | 1 |
| 20 | IL-lpretreatments enhance IFN -alpha-induced Janus kinase STAT-signaling and potentiate the anti- tumor effectes of IFNalpha in a murine model of melignant melanoma 显示文摘 | Lesinki GB Badgwell B Zimmerer J | 2004 | Immano2004，172，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员